Summary: Asthma is a common and potentially serious chronic disease that affects an estimated 300 million individuals worldwide. Inhaled corticosteroids (ICS) have become the mainstay of treatment for chronic asthma since the 1970s. Mometasone furoate (MF) is a new inhaled glucocorticoid indicated for the maintenance treatment of adults and adolescents over 12 years of age with persistent asthma. Features such as high receptor-binding affinity, high protein-binding capacity, high lipophilicity and low oral bioavailability determine the efficacy and favorable safety profile of mometasone. MF has been more effective in treating severe asthma compared to other inhaled steroids. MF administered once daily can lead to increased patient compliance and consequently better asthma control. MF is proven to be effective in reducing oral corticosteroid use, which can reduce the number of side effects. Mometasone furoate therefore represents an interesting therapeutic option in the treatment of chronic bronchial asthma.